脂肪性肝病诊疗规范化的专家建议（2019年修订版）

doi:10.3760/cma.j.issn.1007-3418.2019.10.005

Abstract

National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association[J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.

References

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 实用肝脏病杂志, 2018, 21(2): 177-186. DOI: 10.3969/j.issn.1672-5069.2018.02.007.National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association.Guidelines of prevention and treatment for nonalcoholic fatty liver disease:a 2018 update[J]. J Prac Hepatol, 2018, 21(2): 177-186. DOI: 10.3969/j.issn.1672-5069.2018.02.007.
[2] 中国医师协会脂肪性肝病专家委员会.脂肪性肝病诊疗规范化的专家建议[J]. 中华肝脏病杂志, 2013, 21(9): 652-655. DOI: 10.3760/cma.j.issn.1007-3418.2013.09.002.Expert Committee on the Diagnosis and Management of Fatty Liver Disease, Chinese Medical Association. Recommendation for standardization of diagnosis and treatment of fatty liver disease[J]. Chin J Hepatol, 2013, 21(9): 652-655. DOI10.3760/cma.j.issn.1007-3418.2013.09.002.
[3] Xia MF, Yan HM, He WY, et al.Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content:an improvement method[J]. Obesity (Silver Spring), 2012, 20(2): 444-452. DOI: 10.1038/oby.2011.302.
[4] Stefan N, H?ring HU, Cusi K.Non-alcoholic fatty liver disease:causes, diagnosis, cardiometabolic consequences, and treatment strategies[J]. Lancet Diabetes Endocrinol, 2019, 7(4): 313-324. DOI: 10.1016/s2213-8587(18)30154-2.
[5] 中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会.瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.Chinese Foundation for Hepatitis Prevention and Control, Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association, Liver Disease Committee of Chinese Research Hospital Association.Consensus on clinical application of transient elastography detecting liver fibrosis:a 2018 update[J]. Chin J Hepatol, 2019, 27(3): 182-191. DOI10.3760/cma.j.issn.1007-3418.2019.03.004.
[6] European Association for the Study of the Liver (EASL), European Association for the Study of Diabes(EASD), European Association for the Study of Obesity (EASO).EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol, 2016, 64(6): 1388-1402. DOI:10.1016/j.jhep.2015.11.004.
[7] Kleiner DE, Brunt EM, Van Natta M, et al.Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41(6): 1313-1321. DOI: 10.1002/hep.20701.
[8] 中华医学会内分泌学分会.非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版)[J]. 临床肝胆病杂志, 2018, 34(10): 2103-2108. DOI: 10.3969/j.issn.1001-5256.2018.10.010.Chinese Society of Endocrinology, Chinese Medical Association.Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders(2nd Edition)[J]. J Clin Hepatol, 2018, 34(10): 2103-2108. DOI10.3969/j.issn.1001-5256.2018. 10.010.
[9] 中国营养学会. 中国居民膳食指南2016[M]. 北京: 人民卫生出版社, 2016. Chinese Society of Nutrition. Dietary guidelines for Chinese residents 2016[M].Beijing: People's Health Publishing House, 2016.
[10] 中国超重/肥胖医学营养治疗专家共识编写委员会.中国超重/肥胖医学营养治疗专家共识(2016年版)[J]. 中华糖尿病杂志, 2016, 8(9): 525-540. DOI: 10.3760/cma.j.issn.1674-5809.2016. 09.004.Chinese overweight/Obesity medical nutrition treatment expert consensus writing committe. Expert consensus on medical nutrition therapy for overweight/obesity in China (2016 Edition)[J]. Chin J Diabetes Mellitus, 2016, 8(9): 525-540. DOI10.3760/cma.j.issn.1674-5809.2016.09.004.
[11] 中华医学会健康管理学分会, 中国营养学会, 中国医疗保健国际交流促进会生殖医学分会, 等.超重或肥胖人群体重管理专家共识及团体标准[J]. 中华健康管理学杂志, 2018, 12(3): 200-207. DOI: 10.3760/cma.j.issn.1674-0815.2018.03.003.Chinese Society of Health Management, Chinese Nutrition Society, Reproductive Medicine Branch of China International Exchange and Promotion Association for Medicine and Healthcare, et al. Expert consensus&standard on weight management for overweight or obese people[J]. Chin J Health Manage, 2018, 12(3): 200-207. DOI10.3760/cma.j.issn.1674-0815.2018.03.003.
[12] Garber AJ, Abrahamson MJ, Barzilay JI, et al.Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprensive type 2 diabetes management algorithm-2019 executive summary[J]. Endocr Pract, 2019, 25(1): 69-100. DOI: 10.4158/cs-2018-0535.
[13] Armstrong MJ, Gaunt P, Aithal GP, et al.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN):a multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet, 2016, 387(10019):679-690. DOI: 10.1016/s0140-6736(15)00803-x.
[14] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J]. 中华健康管理学杂志, 2017, 11(1): 7-28. DOI: 10.3760/cma.j.issn.1674-0815.2017.01.003.Joint committee issued Chinese guideline for the management of dyslipidemia in adults. 2016 Chinese guideline for the management of dyslipidemia in adults[J]. Chin J Health Manage, 2017, 11(1): 7-28. DOI10.3760/cma.j.issn.1674-0815.2017.01.003.
[15] Bril F, Portillo Sanchez P, Lomonaco R, et al.Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial[J]. J Clin Endocrinol Metab, 2017, 102(8): 2950-2961. DOI: 10.1210/jc.2017-00867.
[16] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56. DOI: 10.3969/j.issn.1007-5410.2019.01.002.Writing Group of 2018 Chinese Guidelines for the Management of Hypertension, Chinese Hypertension League, Chinese Society of Cardiology, et al. 2018 Chinese guidelines for the management of hypertension[J]. Chin J Cardiovasc Med, 2019, 24(1): 24-56. DOI10.3969/j.issn.1007-5410.2019.01.002.
[17] Sanyal AJ, Chalasani N, Kowdley KV, et al.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 362(18): 1675-1685. DOI: 10.1056/NEJMoa0907929.
[18] Zang S, Chen J, Song Y, et al.Haptoglobin genotype and vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis in China:a multicenter, randomized, placebo-controlled trial design[J]. Adv Ther, 2018, 35(2): 218-231. DOI: 10.1007/s12325-018-0670-8.
[19] 中华医学会外科学分会甲状腺及代谢外科学组, 中国医师协会外科医师分会肥胖和糖尿病外科医师委员会.中国肥胖及2型糖尿病外科治疗指南(2019版)[J]. 中国实用外科杂志, 2019, 39(4): 301-306. DOI: 10.19538/j.cjps.issn1005-2208.2019.04.01.Thyroid and metabolic surgery group, surgical society of Chinese medical association, committee of obesity and diabetes surgeons, surgeon branch, Chinese medical association. Chinese guidelines for surgical treatment of obesity and type 2 diabetes (2019 Edition)[J]. Chinese Journal of Practical Surgery, 2019, 39(4): 301-306. DOI10.19538/j.cjps.issn1005-2208.2019.04.01.
[20] European Association for the Study of the Liver, European Association for the Study of the Liver.EASL clinical practice guidelines:management of alcohol-related liver disease[J]. J Hepatol, 2018, 69(1): 154-181. DOI: 10.1016/j.jhep.2018.03.018.
[21] Vos MB, Abrams SH, Barlow SE, et al.NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the north American society of pediatric gastroenterology, hepatology and nutrition (NASPGHAN)[J]. J Pediatr Gastroenterol Nutr, 2017, 64(2): 319-334. DOI: 10.1097/mpg.0000000000001482.
[22] Wong VW, Wong GL, Chan RS, et al.Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2018, 69(6): 1349-1356. DOI: 10.1016/j.jhep.2018.08.011.
[23] Lin XF, Shi KQ, You J, et al.Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease:a large study[J]. Mol Biol Rep, 2014, 41(5): 2989-2997. DOI: 10.1007/s11033-014-3157-y.
[24] 范建高, 庄辉.中国脂肪肝防治指南(科普版)[M].上海:上海科学技术出版社, 2018. Fan JG, Zhuang H. Guidelines for the prevention and treatment of fatty liver in China (Popular science edition)[M].Shanghai: Shanghai Science and Technology Publishing House, 2018.
[25] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南(2018更新版)[J]. 中华肝脏病杂志, 2018, 26(3): 188-194. DOI: 10.3760/cma.j.issn.1007-3418.2018.03.007.National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association;Fatty Liver Expert Committee, Chinese Medical Doctor Association.Guidelines of prevention and treatment for alcoholic liver disease:a 2018 update[J]. Chin J Hepatol, 2018, 26(3): 188-194. DOI10.3760/cma.j.issn.1007-3418.2018.03.007.

Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[6]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[7]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[8]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[9]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[10]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[11]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[12]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[13]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[14]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[15]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.